Tight Risk Reward, Good Company

NASDAQ:MRSN   Mersana Therapeutics, Inc.
Mersana Therapeutics, Inc., a clinical stage biopharmaceutical company focusing on the development of antibody drug conjugate (ADC) for cancer patients with unmet need.

  • After an insider at Mersana Therapeutics bought shares following a May 2020 selloff triggered by an interim data release, the stock rallied over 400% during the next eight months.
    Another bounce back may emerge again with an insider purchasing shares after a one-day plunge of nearly 30% on tepid but still encouraging data from its lead ADC asset.
    A 180-patient single-arm registrational trial is set to be initiated for XMT-1536 in the treatment of platinum-resistant ovarian cancer this quarter.
    With early-stage clinical data due from both its candidates in the treatment of NSCLC adenocarcinoma in 2H21, Mersana merited another look.

I like it long here as tight risk-reward play.


The information and publications are not meant to be, and do not constitute, financial, investment, trading, or other types of advice or recommendations supplied or endorsed by TradingView. Read more in the Terms of Use.